
wife = @samalanascience fund = @xeia_vp
San Francisco, CA
Joined November 2010
- Tweets2.8K
- Following552
- Followers6.2K
- Likes4.4K
great article about this history of the Thiel Fellowship (including some mentions of yours truly)
Replying to @DStrachman
Permission to Think for Yourself: Inside the Thiel Fellowship's Early Years:
review.firstround.com/inside…
Experimenting with something new in the compute markets (buying/selling/hedging gpu capacity). If you're doing anything remotely related to this and want to chat, please reach out.
brom retweeted
Lily runs a Chinese takeout spot in the Outer Richmond that kicks ass. Her storefront sign recently went SF viral - she had no idea! I went to go show her.
Go visit her! She loves chatting about many different things and getting a chance to learn about others’ lives. A true neighborhood gem. Love you Lily!
Replying to @edwinarbus
Guys, Lily had no idea half a million people saw her restaurant sign. She’s an amazing lady who loves people and is deserving of your visits!
brom retweeted
Foundation models for brain data are a hot topic in the neurotech world.
Hemispheric and its $52M Series A raise catalyzed a lot of hype and assumptions around scaling laws applied to EEG data without any substantial discourse around the obvious representation problem that exists with EEG data. (This was my impression based on the people I spoke with who cited Hemispheric and made erroneous generalizations about what their work meant for neurotech writ large; I never spoke with Hemispheric directly).
Companies like Piramidal, Alljoined, Constellation, and Conduit are just some of the many companies leveraging brain data en masse to build foundation models with interesting applications. Data collection > models > applications. There's a race to the top in terms of who can collect the most data the quickest.
But I remain puzzled for one reason: Neuroscience as a Service (NaaS) is not an established market yet. While I'm excited about all of these companies, I have seen first hand just how much effort is required to get a deal going with a corporate partner and a neurotech. Some founders talk to me about their GTM assumptions, which are very clearly unsubstantiated. Assuming that the market will come to you if you collect enough data is the wrong move here. You have to be trailblazing on the corp dev & BD side of things simultaneously - just like any other startup, distribution is 90% of the battle.
I'm further perturbed by the lack of progress in addressing the representation problem in EEG. I'm optimistic that some companies are using modalities other than EEG (I know some are using td-fNIRS), but I still don't understand how to make the venture case for these models (i.e. generating a significant return in less than ten years) when the hardware moat and physics/engineering insights aren't owned outright by the company.
I recently parted ways with @KernelCo, but I'm still extremely bullish on the tech and have had many conversations about how this company could come out on top as the NVIDIA of neurotech. Kernel was able to accomplish so much over the past 3 years and much of these accomplishments have been under-publicized (which I'm thinking about resolving with my own writing). The company has spent years pioneering what the NaaS offering is. I'm not quite sure anyone else has.
The institutional knowledge that comes with building a completely new modality for brain data collection and trying to commercialize it across several verticals at once is immense.
I'm super bullish on new modalities in neurotech/BCI where the company owns the hardware IP. Hoping to gain a better understanding of who's who in this segment over the next few months.
X's reactions to this photo support my claim
GLP-1 growth will slow once girls start talking like "he was nice, but he gave me the Ozemp-ick"
> The world loves thick
> Men respect thick men
> Women want to be with thick men
> Thick men want thick women
Ut semper fuit
brom retweeted
I wrote this a few weeks ago without any intention of sharing something so personal. I changed my mind.
Excited to share @WonderTxAi 's "de-stealthing"! We backed @AbeHeifets and the rest of the Wonder team back in 2025, when they were referring to themselves as "ACoISM" (a company in stealth mode).
Abe has an incredible track record as a founder, having previously started Atomwise, one of the OG AI drug discovery companies, which raised ~$200M.
Stoked to see what wonderful things Wonder comes up with.
AI-for-drug-discovery should take us beyond the same targets and molecules that everyone already studies. The true benchmark is whether it can make medicines that otherwise would not exist.
We built WonderTx to go after the targets that chemistry has left behind.
wondertx.ai/?utm_source=twit…
brom retweeted
Moderna just showed what mRNA can do beyond vaccines: its individualized cancer therapy, with Keytruda, succeeded in Ph3.
When LLMs began rapidly progressing 3y ago, we made a bet that AI models can outperform human-led design to create better mRNAs. 🧵1/4
Replying to @EricTopol
Despite its obvious misuse during Covid, mRNA has tremendous promise for curing diseases.
Artificial RNA essentially makes curing diseases a software problem.
while the rest of the world was hating on/sleeping on mRNA - we backed @KernaLabs , founded by the former CSO of Moderna along with @AmitDeshwar and @juliapeng__
Watch this space
BREAKING: Moderna stock, $MRNA, surges over +110% after announcing the first ever positive Phase 3 results for a personalized cancer vaccine.
brom retweeted
Today I am announcing my plans to cure all chorizos guanciales and prosciuttos within the next ~5-10 years



























